Patents by Inventor Mary T. Am Ende

Mary T. Am Ende has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0.0]-hexadeca-2(11),3,5,7,9-pentaene
    Patent number: 7771748
    Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: August 10, 2010
    Assignee: Pfizer Inc
    Inventors: Mary T. Am Ende, Michael C. Roy, Scott W. Smith, Kenneth C. Waterman, Sara Kristen Moses
  • Sustained release formulations for growth hormone secretagogues
    Publication number: 20040091530
    Abstract: The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation.
    Type: Application
    Filed: June 30, 2003
    Publication date: May 13, 2004
    Inventors: Mary T. Am Ende, William J. Curatolo, Scott M. Herbig
  • Sustained release formulations for growth hormone secretagogues
    Patent number: 6641840
    Abstract: The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: November 4, 2003
    Assignee: Pfizer Inc.
    Inventors: Mary T. Am Ende, William J. Curatolo, Scott M. Herbig
  • Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene
    Publication number: 20030180360
    Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.
    Type: Application
    Filed: November 20, 2002
    Publication date: September 25, 2003
    Applicant: Pfizer Inc.
    Inventors: Mary T. Am Ende, Michael C. Roy, Scott W. Smith, Kenneth C. Waterman, Ernest S. Quan, Sara Kristen Moses
  • Sustained release formulations for growth hormone secretagogues
    Publication number: 20020137765
    Abstract: The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation.
    Type: Application
    Filed: August 27, 2001
    Publication date: September 26, 2002
    Inventors: Mary T. Am Ende, William J. Curatolo, Scott M. Herbig